A recent study presented at the Endocrine Society's annual meeting suggests that semaglutide, a medication used for type 2 diabetes and weight loss, may help protect bones even as patients shed pounds. Researchers found that people taking semaglutide experienced a 15% reduction in fractures compared to those using other weight-loss medications, despite achieving greater weight loss overall. This finding challenges a common concern: that rapid weight loss increases the risk of broken bones.

Why Does Weight Loss Typically Increase Fracture Risk in Diabetes?

People with type 2 diabetes face a unique bone health challenge. When they lose weight through diet or medication, their bodies experience accelerated bone loss, which can weaken bones and increase the likelihood of fractures. This paradox means that while weight loss is medically beneficial for managing diabetes, it can come at a cost to skeletal health. The new research on semaglutide suggests this trade-off may not be inevitable.

What Did the Study Find?

Researchers at Stanford University analyzed electronic health records from over 17,500 adults with type 2 diabetes who had never experienced a fracture and were not taking osteoporosis medications. The study compared people taking semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, to those using three other weight-loss medications: phentermine and topiramate, bupropion and naltrexone, or dulaglutide, another GLP-1 medication. Over an average follow-up period of more than three and a half years, the semaglutide group experienced 794 fractures, while the comparison group experienced 1,045 fractures.

The semaglutide group also achieved greater weight loss than the other groups. This dual benefit,more weight loss paired with fewer fractures,distinguishes semaglutide from the other medications tested.

"We found that semaglutide compared to other weight loss medications, including another GLP-1 medication called dulaglutide, reduced risk of future fractures despite being associated with greater weight loss," said Sun H Kim, MD, MS, Associate Professor of Medicine in the Division of Endocrinology, Gerontology, and Metabolism at Stanford.

Sun H Kim, MD, MS, Associate Professor of Medicine, Stanford University

What Are the Study's Limitations?

While the findings are promising, experts emphasize that the research has important constraints. The study used retrospective data from electronic health records, meaning researchers looked backward at existing information rather than conducting a controlled experiment. Additionally, the analysis included only participants treated at academic medical centers and community hospitals, which may not represent the broader population. Researchers also lacked complete body mass index (BMI) data for many participants, and the study did not distinguish between different types of fractures, such as hip, spine, or wrist breaks.

Because these results have not yet been published in a peer-reviewed journal, they should be interpreted as preliminary findings that warrant further investigation.

• Study Design: Retrospective analysis using electronic health records rather than a randomized controlled trial
• Data Completeness: Missing body mass index information for many participants and incomplete fracture classification by type
• Population Scope: Limited to patients at academic medical centers and community hospitals, which may not generalize to all populations
• Confounding Variables: Researchers may not have accounted for all factors influencing fracture risk, such as physical activity, calcium intake, or vitamin D levels

What Do Experts Say About These Findings?

Orthopedic specialists and bariatric surgeons caution that while the results are encouraging, they should not yet change clinical practice. The findings are "hypothesis-generating rather than practice-changing," according to bone health experts, meaning they suggest a direction for future research but do not provide definitive proof.

"The study suggests that semaglutide does not appear to increase fracture risk and may potentially reduce it, but randomized prospective studies with bone mineral density, bone turnover markers, and fracture endpoints will be needed before concluding that semaglutide has true bone-protective properties," noted Burak Altintas, MD, an orthopedist.

Burak Altintas, MD, Orthopedist

Experts also stress that it remains unclear whether semaglutide's bone-protective effect comes from the medication itself or simply from the fact that people using it lose weight more effectively. Bariatric surgeons point out that similar bone health outcomes have been observed in patients who achieve healthy weight through other means, such as surgery.

What Could This Mean for Future Treatment?

If future research confirms that semaglutide truly protects bone health independent of weight loss, the implications could be significant. Clinicians might become more confident prescribing semaglutide to people with type 2 diabetes who are at elevated risk for fractures. Additionally, as GLP-1 receptor agonists become increasingly popular for weight loss and diabetes management, understanding their effects on bone health becomes increasingly important, particularly for older adults and postmenopausal women who already face higher fracture risk.

The next step will be conducting prospective, randomized controlled trials that measure bone mineral density, bone turnover markers, and fracture outcomes directly. Until then, this research serves as an important signal that semaglutide may offer an advantage over other weight-loss medications for people with type 2 diabetes who are concerned about bone health.